Investigation Report on China Imatinib Mesylate Market, 2010-2019
Description
The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers. The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old.
Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA’s express approval with the trade name of Gleevec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first-line treatment for chronic myelogenous leukemia under FDA’s approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.
After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.
Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China’s economy develops, people’s income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.
Readers can get at least the following information through this report:
The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers. The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old.
Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA’s express approval with the trade name of Gleevec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first-line treatment for chronic myelogenous leukemia under FDA’s approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.
After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.
Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China’s economy develops, people’s income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.
Readers can get at least the following information through this report:
- market size of Imatinib Mesylate in China
- major manufacturers of Imatinib Mesylate in the Chinese market and their market share
- retail price of Imatinib Mesylate in China
- market outlook of Imatinib Mesylate in China
- manufacturers of leukemia drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF IMATINIB MESYLATE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF IMATINIB MESYLATE IN CHINA
2.1 Patent and Approval Status of Imatinib Mesylate in China
2.2 Major Manufacturers
2.3 Market Size
2.4 Smuggled Imatinib Mesylate in Chinese Market
3 SURVEY ON SALES STATUS OF IMATINIB MESYLATE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF IMATINIB MESYLATE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF IMATINIB MESYLATE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms of Imatinib Mesylate by Sales Value
5.2 Share of Different Dosage Forms of Imatinib Mesylate by Sales Volume
6 REFERENCE PRICE OF IMATINIB MESYLATE IN CHINESE HOSPITALS IN 2014
6.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Ge Ni Ke)
6.2 Hansoh Pharmaceutical (Trade Name: Xin Wei)
6.3 Novartis (Swiss) (Trade Name: Gleevec)
7 MAJOR MANUFACTURERS OF IMATINIB MESYLATE IN CHINESE MARKET, 2010-2014
Hansoh Pharmaceutical; Chia Tai Tianqing Pharmaceutical Group Co., LtdNovartis
8 MARKET OUTLOOK OF IMATINIB MESYLATE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF IMATINIB MESYLATE IN CHINA
2.1 Patent and Approval Status of Imatinib Mesylate in China
2.2 Major Manufacturers
2.3 Market Size
2.4 Smuggled Imatinib Mesylate in Chinese Market
3 SURVEY ON SALES STATUS OF IMATINIB MESYLATE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF IMATINIB MESYLATE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF IMATINIB MESYLATE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms of Imatinib Mesylate by Sales Value
5.2 Share of Different Dosage Forms of Imatinib Mesylate by Sales Volume
6 REFERENCE PRICE OF IMATINIB MESYLATE IN CHINESE HOSPITALS IN 2014
6.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Ge Ni Ke)
6.2 Hansoh Pharmaceutical (Trade Name: Xin Wei)
6.3 Novartis (Swiss) (Trade Name: Gleevec)
7 MAJOR MANUFACTURERS OF IMATINIB MESYLATE IN CHINESE MARKET, 2010-2014
Hansoh Pharmaceutical; Chia Tai Tianqing Pharmaceutical Group Co., LtdNovartis
8 MARKET OUTLOOK OF IMATINIB MESYLATE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
SELECTED CHARTS
Chart Patent Status of Imatinib Mesylate in China
Chart Approval Information of Imatinib Mesylate in China
Chart Sales Status of Imatinib Mesylate in China, 2010-2014
Chart Sales Value of Imatinib Mesylate in China, 2010-2014
Chart Sales Value of Imatinib Mesylate in Some Regions in China, 2010-2014
Chart Sales Volume of Imatinib Mesylate in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Imatinib Mesylate for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Novartis in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Hansoh in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Tablets in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Capsules in China, 2010-2014
Chart Price of Imatinib Mesylate Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Imatinib Mesylate Made by Hansoh Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Imatinib Mesylate Made by Novartis (Swiss) in Some Chinese Cities in 2014
Chart Patent Status of Imatinib Mesylate in China
Chart Approval Information of Imatinib Mesylate in China
Chart Sales Status of Imatinib Mesylate in China, 2010-2014
Chart Sales Value of Imatinib Mesylate in China, 2010-2014
Chart Sales Value of Imatinib Mesylate in Some Regions in China, 2010-2014
Chart Sales Volume of Imatinib Mesylate in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Imatinib Mesylate for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Novartis in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Hansoh in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Tablets in China, 2010-2014
Chart Sales Value and Market Share of Imatinib Mesylate Capsules in China, 2010-2014
Chart Price of Imatinib Mesylate Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Imatinib Mesylate Made by Hansoh Pharmaceutical in Some Chinese Cities in 2014
Chart Price of Imatinib Mesylate Made by Novartis (Swiss) in Some Chinese Cities in 2014
